1342. Reliability and Reproducibility of Lesion Size Measurements in Patients with Skin Abscesses or Cellulitis
Session: Poster Abstract Session: Clinical Trials
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • Reliability and Reproducibility of Lesion Size Measurements in Patients with Skin Abscesses or Cellulitis (Powers et al.) IDWeek 2013.pdf (392.4 kB)
  • Background: Reduction in skin lesion size is the primary endpoint for ABSSSI trials. A study with oral tedizolid phosphate (TZP) 200 mg QD for 6 days for ABSSSI was conducted to assess the reliability and reproducibility of different lesion measurement methods using a flexible plastic ruler.

    Methods: Three methods of measuring lesion area were compared: 1) inter-observer variability, 2) correlation of lesion size defined by erythema alone versus combining erythema, edema, and/or induration (erythema+); and 3) correlation of measuring the length of the lesion along the head-to-toe axis versus the longest length axis. Lesion areas were measured with a flexible plastic ruler at the baseline and 48-72 hour visits.

    Results: Lesion measurements were highly correlated when measured by 2 different observers, and were also similar whether a head-to-toe or longest length axis was used for orientation, or whether the extent of the lesion was defined by erythema alone versus erythema+ is presented in the table below.

    Description: Macintosh HD:Users:jsimoes:Desktop:Untitled.jpg

    Conclusion: The reliability of measuring skin lesion areas in patients with ABSSSI with a plastic ruler showed low inter-observer variability. This was true regardless of orientation used to determine length or if erythema alone versus erythema+, supporting the use of a simple plastic ruler to determine lesion size in ABSSSI clinical trials.

    John Powers, MD, FIDSA1, Carisa De Anda, PharmD2, Cara Casseday3, Anita Das, PhD4, Edward Fang, MD3 and Philippe Prokocimer, MD3, (1)Medicine, George Washington University School of Medicine, Bethesda, MD, (2)Trius Therapeutics, San Diego, CA, (3)Trius Therapeutics, Inc, San Diego, CA, (4)Axistat Inc, San Francisco, CA

    Disclosures:

    J. Powers, None

    C. De Anda, None

    C. Casseday, None

    A. Das, None

    E. Fang, None

    P. Prokocimer, None

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.